RU2015144107A - Gla домены в качестве нацеливающих агентов - Google Patents

Gla домены в качестве нацеливающих агентов Download PDF

Info

Publication number
RU2015144107A
RU2015144107A RU2015144107A RU2015144107A RU2015144107A RU 2015144107 A RU2015144107 A RU 2015144107A RU 2015144107 A RU2015144107 A RU 2015144107A RU 2015144107 A RU2015144107 A RU 2015144107A RU 2015144107 A RU2015144107 A RU 2015144107A
Authority
RU
Russia
Prior art keywords
domain
virus
cancer
polypeptide
gla
Prior art date
Application number
RU2015144107A
Other languages
English (en)
Other versions
RU2711091C2 (ru
Inventor
Максин БОЗОН
Терри ХЕРМИСТОН
Original Assignee
Байер Хелскеа Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Хелскеа Ллк filed Critical Байер Хелскеа Ллк
Publication of RU2015144107A publication Critical patent/RU2015144107A/ru
Application granted granted Critical
Publication of RU2711091C2 publication Critical patent/RU2711091C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)

Claims (38)

1. Способ нацеливания на фосфатидилсерин (PtdS) клеточной мембраны, который включает:
(a) обеспечение изолированного полипептида, включающего домен гамма-карбоксиглутаминовой кислоты (Gla) и не имеющего домена протеазы или гормонсвязывающего домена; и
(b) приведение в контакт указанного пептида с поверхностью клетки,
где указанный полипептид связывается с PtdS на указанной клеточной мембране.
2. Способ по п. 1, где указанная клеточная мембрана представляет собой мембрану кардиомиоцита, мембрану нейронной клетки, мембрану эндотелиальной клетки, мембрану инфицированной вирусом клетки, мембрану апоптической клетки, мембрану тромбоцита или мембрану раковой клетки.
3. Способ по п. 1, где указанный полипептид дополнительно включает домен, связывающий EGF.
4. Способ по п. 1, где указанный полипептид дополнительно включает Крингл домен.
5. Способ по п. 1, где указанный полипептид дополнительно включает домен блока ароматической аминокислоты.
6. Способ по п. 1, где указанный Gla домен представляет собой Gla домен из фактора II, фактора VII, фактора IX, фактора X, белка S или белка С.
7. Способ по п. 1, где указанный полипептид дополнительно включает способную к определению метку.
8. Способ по п. 7, где указанная способная к определению метка представляет собой флуоресцентную метку, хемилюминисцентную метку, радиоактивную метку, фермент, краситель или лиганд.
9. Способ по п. 1, где указанный полипептид дополнительно включает терапевтический агент.
10. Способ по п. 9, где указанный терапевтический агент представляет собой противораковый агент.
11. Способ по п. 10, где указанный противораковый агент представляет собой химиотерапевтический, радиотерапевтический агент, цитокин, гормон, антитело или фрагмент антитела или токсин.
12. Способ по п. 9, где указанный терапевтический агент представляет собой противовирусный агент.
13. Способ по п. 9, где терапевтический агент представляет собой фермент, такой, как фермент, превращающий пролекарственное средство.
14. Способ по п. 9, где терапевтический агент представляет собой цитокин, фактор роста, фактор коагуляции крови или антикоагулянт.
15. Способ по п. 1, где указанный полипептид содержит 300 остатков или менее, 200 остатков или менее или 100 остатков или менее.
16. Способ по п. 1, где указанный полипептид включает 5-15 остатков Gla.
17. Способ по п. 1, где указанный полипептид включает 9-13 остатков Gla.
18. Способ по п. 1, где указанный полипептид включает более чем 13 остатков Gla, но менее чем 30% от общего количества остатков Gla.
19. Способ по п. 1, где указанный полипептид имеет размер приблизительно от 4,5 до 30 кДа.
20. Способ по п. 1, где указанный полипептид включает, по крайне мере, одну дисульфидную связь.
21. Способ по п. 1, где указанный полипептид включает 2-5 дисульфидных связей.
22. Способ по п. 1, где указанный полипептид включает Gla домен белка S.
23. Способ по п. 1, где указанный полипептид включает Gla домен белка S и EGF домен белка S.
24. Способ по п. 1, где указанный полипептид включает Gla домен протромбина.
25. Способ по п. 1, где указанный полипептид включает Gla домен протромбина плюс Крингл домен протромбина.
26. Способ по п. 1, где указанный полипептид включает Gla домена белка Z.
27. Способ по п. 1, где указанный полипептид включает Gla домен белка Z плюс Крингл домен протромбина.
28. Способ по п. 1, где указанный полипептид включает Gla домен фактора VII.
29. Способ по п. 1, где указанный полипептид включает Gla домен фактора VII плюс Крингл домен протромбина.
30. Способ по п. 1, где указанный полипептид дополнительно включает Fc участок антитела.
31. Способ лечения рака у субъекта, включающий введение указанному субъекту изолированного полипептида, включающего домен гамма-карбоксиглутаминовой кислоты (Gla) и не имеющего домена протеазы или гормонсвязывающего домена, где указанный полипептид является связанным с терапевтической загрузкой.
32. Способ по п. 31, где указанная терапевтическая загрузка представляет собой химиотерапевтический агент, радиотерапевтический агент или токсин.
33. Способ по п. 31, где указанный рак представляет собой рак молочной железы, рак мозга, рак желудка, рак легких, рак предстательной железы, рак яичников, тестикулярный рак, рак толстой кишки, рак кожи, рак прямой кишки, рак шейки матки, рак матки, рак печени, рак поджелудочной железы, рак головы и шеи или рак пищевода.
34. Способ лечения вирусного заболевания у субъекта, включающий введение указанному субъекту изолированного полипептида, включающего домен гамма-карбоксиглутаминовой кислоты (Gla) и не имеющего домена протеазы или гормонсвязывающего домена, где указанный полипептид является связанным с противовирусным агентом.
35. Способ по п. 34, где указанное вирусное заболевание представляет собой вирус гриппа, вирус иммунодефицита человека, вирус лихорадки денге, вирус Западного Нила, вирус оспы, респираторно-синцитиальный вирус, вирус корейской геморрагической лихорадки, авипоксивирус, вирус ветряной оспы, вирус простого герпеса 1 или 2, вирус Эпштейна-Барр, вирус марбургской болезни, хантавирус, вирус желтой лихорадки, вирус гепатита А, В, С или Е, вирус Эбола, вирус папилломы человека, риновирус, вирус Коксаки, вирус полиомиелита, вирус кори, вирус краснухи, вирус бешенства, вирус ньюкаслской болезни, ротавирус, HTLV-1 и -2.
RU2015144107A 2013-03-15 2014-03-13 Gla домены в качестве нацеливающих агентов RU2711091C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361791537P 2013-03-15 2013-03-15
US201361787753P 2013-03-15 2013-03-15
US61/791,537 2013-03-15
US61/787,753 2013-03-15
PCT/US2014/025940 WO2014151535A1 (en) 2013-03-15 2014-03-13 Gla domains as targeting agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019143609A Division RU2731507C1 (ru) 2013-03-15 2014-03-13 Gla домены в качестве нацеливающих агентов

Publications (2)

Publication Number Publication Date
RU2015144107A true RU2015144107A (ru) 2017-04-28
RU2711091C2 RU2711091C2 (ru) 2020-01-15

Family

ID=51580982

Family Applications (3)

Application Number Title Priority Date Filing Date
RU2019143609A RU2731507C1 (ru) 2013-03-15 2014-03-13 Gla домены в качестве нацеливающих агентов
RU2015144107A RU2711091C2 (ru) 2013-03-15 2014-03-13 Gla домены в качестве нацеливающих агентов
RU2015144097A RU2705786C2 (ru) 2013-03-15 2014-03-13 Gla домены в качестве терапевтических агентов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2019143609A RU2731507C1 (ru) 2013-03-15 2014-03-13 Gla домены в качестве нацеливающих агентов

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015144097A RU2705786C2 (ru) 2013-03-15 2014-03-13 Gla домены в качестве терапевтических агентов

Country Status (25)

Country Link
US (6) US10894075B2 (ru)
EP (5) EP2970429B1 (ru)
JP (4) JP6471385B2 (ru)
CN (2) CN105164152B (ru)
AU (2) AU2014233885B2 (ru)
BR (2) BR112015021866A2 (ru)
CA (3) CA2905972C (ru)
CY (2) CY1126074T1 (ru)
DK (4) DK3524617T3 (ru)
ES (4) ES2945160T3 (ru)
FI (2) FI3524617T3 (ru)
HK (2) HK1215263A1 (ru)
HR (2) HRP20230632T1 (ru)
HU (2) HUE062021T2 (ru)
IL (3) IL240530B (ru)
MX (3) MX2015011873A (ru)
MY (2) MY193211A (ru)
PE (2) PE20152005A1 (ru)
PL (3) PL3524617T3 (ru)
PT (2) PT3524618T (ru)
RU (3) RU2731507C1 (ru)
SA (1) SA515361061B1 (ru)
SG (3) SG11201506880WA (ru)
WO (2) WO2014151683A1 (ru)
ZA (2) ZA201507670B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011873A (es) * 2013-03-15 2016-01-25 Bayer Healthcare Llc Dominios gla como agentes de direccionamiento.
WO2015170778A1 (ja) * 2014-05-08 2015-11-12 学校法人日本大学 ホスファチジルセリンの細胞表面への表出促進剤又は表出抑制剤、及び脂質ラフトのクラスター形成抑制剤
CN104745649B (zh) * 2015-02-28 2018-03-09 苏州汉酶生物技术有限公司 一种福沙那韦中间体的生物制备方法
CN104784179A (zh) * 2015-04-01 2015-07-22 重庆理工大学 替拉那韦在抗乳腺癌药物中的应用及抗乳腺癌药物
EP3464322B1 (en) * 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
EP3658186A4 (en) * 2017-07-24 2020-08-12 Rutgers, The State University of New Jersey FUSION MOLECULES TARGETING PHOSPHATIDYLSERINE AND THEIR METHODS OF USE
AU2018328223A1 (en) * 2017-09-05 2020-03-12 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
CN108159421B (zh) * 2018-02-05 2021-05-18 苏州大学 磷脂酰丝氨酸阻断剂在制备治疗血小板数量减少相关疾病药物中的用途
EP3756010A4 (en) * 2018-02-20 2021-11-03 Pavonis Diagnostics Inc. ALUMINUM OXIDE SURFACES AND INTERFACE MOLECULES
KR20210060574A (ko) * 2018-10-22 2021-05-26 아사히 가세이 파마 가부시키가이샤 응고 이상을 수반하는 패혈증의 치료 및/또는 개선을 위한 의약
CN113061169B (zh) * 2020-03-24 2022-09-27 江南大学 一种转录调控蛋白及其在共轭亚油酸生产中的应用
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
RU2768194C1 (ru) * 2021-08-02 2022-03-23 федеральное государственное бюджетное образовательное учреждение высшего образования "Нижегородский государственный технический университет им. Р.Е. Алексеева" (НГТУ) Способ оценки степени экстернализации фосфатидилсерина на поверхность мембран эритроцитов
WO2023076620A1 (en) * 2021-10-29 2023-05-04 Sigilon Therapeutics, Inc. Compositions for cell-based therapies and related methods
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
WO2023192362A1 (en) * 2022-03-31 2023-10-05 Incelldx, Inc. Methods of treating a subject for myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs) and compositions for use in the same

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
EP0573608A1 (en) 1991-02-07 1993-12-15 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US6261569B1 (en) 1992-08-27 2001-07-17 Deakin Research Limited Retro-, inverso- and retro-inverso synthetic peptide analogues
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
EP0706564A1 (en) * 1993-06-30 1996-04-17 Rijksuniversiteit Leiden Protein s deletion variants deficient in c4bp binding activity, but having apc cofactor activity, compositions and therapeutic methods
US5597457A (en) 1995-01-23 1997-01-28 The Regents Of The University Of California System and method for forming synthetic protein crystals to determine the conformational structure by crystallography
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CA2276091A1 (en) 1996-12-27 1998-07-09 Mochida Pharmaceutical Co., Ltd. Cell membrane-directed drugs
US6093573A (en) 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6459996B1 (en) 1998-08-13 2002-10-01 American Home Products Corporation Crystal structure of E. coli GDP-fucose synthetase (and complexes thereof) and methods of identifying agonists and antagonists using same
IL141510A0 (en) 1998-08-25 2002-03-10 Scripps Research Inst Method and systems for predicting protein function
US6801860B1 (en) 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
JP2002003407A (ja) 2000-06-20 2002-01-09 Medei Sci Puraningu:Kk ハイドロキシアパタイトカルシウム指向性薬物輸送担体
WO2003017032A2 (en) 2001-08-14 2003-02-27 Dana-Farber Cancer Institute, Inc. Computer-based methods of designing molecules
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
BRPI0409497A (pt) * 2003-04-18 2006-05-02 Novartis Ag métodos e composições que alvejam tirosina cinases para a diagnose e tratamento de osteoartrite
CN1839203B (zh) * 2003-06-19 2011-11-16 拜耳医药保健有限公司 因子VII或VIIa的GLA结构域变体
JP2007523099A (ja) * 2004-02-20 2007-08-16 ノボ　ノルディスク　アクティーゼルスカブ 組み合わせ療法
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
RU2396347C2 (ru) * 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
EP1853631B1 (en) * 2005-01-24 2016-03-09 Board of Regents, The University of Texas System Fc FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC USE
JP2008531059A (ja) 2005-03-04 2008-08-14 バイオレクシス ファーマシューティカル コーポレーション 改変トランスフェリン融合タンパク質
WO2007047504A2 (en) 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins
US7624557B2 (en) * 2006-05-02 2009-12-01 Box Partition Technologies, Inc. Assembling machine with continuous periodic assembly motion
PL2147096T3 (pl) * 2007-04-13 2015-08-31 Catalyst Biosciences Inc Zmodyfikowane polipeptydy czynnika VII i ich zastosowania
KR100968839B1 (ko) 2008-02-25 2010-07-09 경북대학교 산학협력단 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의용도
WO2010006136A2 (en) * 2008-07-09 2010-01-14 Mayo Foundation For Medical Education And Research Adenovirus targeting
EP2311864A4 (en) * 2008-08-13 2013-07-31 Kyowa Hakko Kirin Co Ltd RECOMBINANT PROTEIN-S COMPOSITION
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US8283167B2 (en) 2009-02-11 2012-10-09 Clear Vascular Inc. Preparation of annexin derivatives
ES2524974T3 (es) 2009-06-25 2014-12-16 The University Of North Carolina At Chapel Hill Moléculas del Factor VII quimérico
SG190450A1 (en) 2010-12-20 2013-06-28 Agency Science Tech & Res Method of purifying exosomes
WO2012120130A1 (en) 2011-03-09 2012-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods to characterize patients suffering from hemolysis
TR201811128T4 (tr) 2011-07-18 2018-08-27 Iba Gmbh Bir hedef hücrenin tersinir şekilde boyama yöntemi.
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
US9406314B1 (en) 2012-10-04 2016-08-02 Magnecomp Corporation Assembly of DSA suspensions using microactuators with partially cured adhesive, and DSA suspensions having PZTs with wrap-around electrodes
MX2015011873A (es) * 2013-03-15 2016-01-25 Bayer Healthcare Llc Dominios gla como agentes de direccionamiento.
CA2985369A1 (en) 2015-05-14 2016-11-17 J.R. Simplot Company Potato cultivar v11
WO2017118764A1 (en) 2016-01-07 2017-07-13 Thomas Brocker Novel approaches for the in vivo and in vitro visualization of dying cells
AU2018328223A1 (en) 2017-09-05 2020-03-12 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells

Also Published As

Publication number Publication date
US20190105370A1 (en) 2019-04-11
JP2016513463A (ja) 2016-05-16
AU2014233885A1 (en) 2015-09-17
CN105008397B (zh) 2021-07-06
US20210113657A1 (en) 2021-04-22
CY1126074T1 (el) 2023-11-15
IL240841A0 (en) 2015-10-29
NZ751494A (en) 2021-07-30
CA2905986A1 (en) 2014-09-25
EP3524617A1 (en) 2019-08-14
RU2705786C2 (ru) 2019-11-11
JP6595977B2 (ja) 2019-10-23
CN105008397A (zh) 2015-10-28
US20160008482A1 (en) 2016-01-14
SG11201506880WA (en) 2015-09-29
PT3524617T (pt) 2023-07-12
EP2970442A4 (en) 2016-08-31
EP2970442A1 (en) 2016-01-20
EP3524617B1 (en) 2023-04-12
MY193211A (en) 2022-09-26
EP2970429A4 (en) 2016-08-31
DK2970429T3 (da) 2019-11-18
EP3524618A1 (en) 2019-08-14
HUE062055T2 (hu) 2023-09-28
IL270353A (en) 2022-12-01
FI3524618T3 (fi) 2023-05-29
AU2014233885B2 (en) 2018-08-09
DK3524618T3 (da) 2023-06-06
CA2905972A1 (en) 2014-09-25
CA3128999C (en) 2023-09-12
EP3524618B1 (en) 2023-03-08
DK3524617T3 (da) 2023-05-15
ES2945160T3 (es) 2023-06-28
SA515361061B1 (ar) 2019-09-22
BR112015021866A2 (pt) 2017-08-29
NZ751491A (en) 2021-07-30
PT3524618T (pt) 2023-06-06
HK1215263A1 (zh) 2016-08-19
AU2014236990A8 (en) 2017-12-21
HRP20230527T1 (hr) 2023-08-04
SG10201913166SA (en) 2020-02-27
PL2970429T3 (pl) 2020-04-30
HK1216649A1 (zh) 2016-11-25
US9694048B2 (en) 2017-07-04
JP2020015752A (ja) 2020-01-30
AU2014236990B2 (en) 2019-03-07
AU2014236990A1 (en) 2015-09-10
IL240530B (en) 2019-11-28
JP6471385B2 (ja) 2019-02-20
JP6812403B2 (ja) 2021-01-13
WO2014151683A8 (en) 2015-10-01
SG11201506307XA (en) 2015-09-29
CA3128999A1 (en) 2014-09-25
ES2728863T3 (es) 2019-10-29
DK2970442T3 (da) 2019-06-17
EP2970442B1 (en) 2019-03-06
PE20152020A1 (es) 2016-01-29
JP2016516037A (ja) 2016-06-02
PL3524617T3 (pl) 2023-07-17
US10925926B2 (en) 2021-02-23
NZ712058A (en) 2021-07-30
MY176901A (en) 2020-08-26
ZA201507670B (en) 2017-11-29
BR112015021869A2 (pt) 2017-08-29
WO2014151683A1 (en) 2014-09-25
PE20152005A1 (es) 2016-01-29
IL240841B (en) 2020-06-30
CY1126072T1 (el) 2023-11-15
FI3524617T3 (fi) 2023-06-26
US20160106806A1 (en) 2016-04-21
RU2731507C1 (ru) 2020-09-03
JP2019069994A (ja) 2019-05-09
US20170296624A1 (en) 2017-10-19
US10894075B2 (en) 2021-01-19
NZ710958A (en) 2021-07-30
CA2905972C (en) 2021-10-26
MX2021009450A (es) 2021-12-10
HUE062021T2 (hu) 2023-09-28
RU2711091C2 (ru) 2020-01-15
WO2014151535A1 (en) 2014-09-25
MX2015011873A (es) 2016-01-25
RU2015144097A (ru) 2017-04-24
HRP20230632T1 (hr) 2023-09-29
CN105164152A (zh) 2015-12-16
ES2756532T3 (es) 2020-04-27
EP2970429B1 (en) 2019-10-23
EP4174082A1 (en) 2023-05-03
MX2015011409A (es) 2016-02-03
PL3524618T3 (pl) 2023-07-10
ES2945994T3 (es) 2023-07-11
EP2970429A1 (en) 2016-01-20
IL270353B2 (en) 2023-04-01
CN105164152B (zh) 2021-07-06
US20210015900A1 (en) 2021-01-21
ZA201507674B (en) 2017-08-30

Similar Documents

Publication Publication Date Title
RU2015144107A (ru) Gla домены в качестве нацеливающих агентов
JP2016513463A5 (ja) 治療剤としてのＧｌａドメイン
CY1122195T1 (el) Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων
RU2014143639A (ru) Регулируемые протеазой антитела
RU2014104302A (ru) Слитые белки, высвобождающие релаксин, и их применение
WO2016004906A2 (zh) 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用
RU2012137498A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
MX2012007318A (es) Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia.
RU2009148886A (ru) Рсв-специфичные связывающие молекулы и средства для их получения
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
BRPI0417159A (pt) produção de partìcula semelhante a vìrus icosaédrico recombinante em pseudomÈnades
DE60043547D1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
RU2015151872A (ru) Пептиды с антагонистической активностью в отношении природного cxcr4
CN105367661B (zh) 嵌合抗原受体及其基因和重组表达载体、工程化her1靶向性的nkt细胞及其应用
WO2008109686A8 (en) Non- infectious recombinant virus-like particles and their pharmaceutical applications
JP2020524141A5 (ru)
FI20050753A0 (fi) Uudet peptidit
CN105924526B (zh) 嵌合抗原受体及其基因和重组表达载体、carher1-nkt细胞及其制备方法和应用
CN104560894B (zh) 编码分泌介导效应细胞杀伤靶细胞的双特异分子的框架及病毒
JP2013517782A5 (ru)
TH153734A (th) แอนตี้-ฮิวแมน ngf แอนตี้บอดี้ใหม่
JP5312747B2 (ja) Ｈｖｊエンベロープによるタンパク質の導入方法
CN105920616B (zh) Carher1-nkt细胞在制备用于治疗进展期her1阳性胆管癌的制剂中的应用
TH138888A (th) แอนทาโกนิสต์ของ il-6 เพื่อเพิ่มอัลบูมิน และ/หรือ ลด crp
TH179718A (th) แอนติบอดีของมนุษย์ต่อเรสไพราทอรีซินไซเทียลไวรัส f โปรตีน และวิธีการใช้ของมัน

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant